O

Otonomy Inc
F:7OT

Watchlist Manager
Otonomy Inc
F:7OT
Watchlist
Price: 0.0626 EUR 0.64%
Market Cap: 11.4m EUR

Operating Margin
Otonomy Inc

0%
Current
-24 371%
Average
5.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-50.9m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Otonomy Inc
F:7OT
11.4m EUR N/A
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
514.1B USD
27%
CH
Roche Holding AG
SIX:ROG
273.5B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
221.3B GBP
24%
CH
Novartis AG
SIX:NOVN
219.8B CHF
33%
US
Merck & Co Inc
NYSE:MRK
269.3B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
143B USD
29%
No Stocks Found

Otonomy Inc
Glance View

Market Cap
11.4m EUR
Industry
Pharmaceuticals

Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.

7OT Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-50.9m
/
Revenue
0
What is the Operating Margin of Otonomy Inc?

Based on Otonomy Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top